| Year |
Citation |
Score |
| 2022 |
Qureshi R, Picon-Ruiz M, Sho M, Van Booven D, Nunes de Paiva V, Diaz-Ruano AB, Ince TA, Slingerland J. Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis. Cell Reports. 41: 111672. PMID 36384125 DOI: 10.1016/j.celrep.2022.111672 |
0.32 |
|
| 2022 |
Kurani H, Razavipour SF, Harikumar KB, Dunworth M, Ewald AJ, Nasir A, Pearson G, van Booven D, Zhou Z, Azzam D, Wahlestedt C, Slingerland J. DOT1L is a novel cancer stem cell target for triple negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35135840 DOI: 10.1158/1078-0432.CCR-21-1299 |
0.743 |
|
| 2021 |
Jiang X, Lu X, Gentles AJ, Zhao D, Wander SA, Zhang Y, Natkunam Y, Slingerland J, Reis IM, Rabinovich B, Abdulreda MH, Moy VT, Lossos IS. HGAL inhibits lymphoma dissemination by interacting with multiple Cytoskeletal proteins. Blood Advances. PMID 34543391 DOI: 10.1182/bloodadvances.2021004304 |
0.605 |
|
| 2020 |
Picon-Ruiz M, Marchal JA, Slingerland JM. Obtaining Human Breast Adipose Cells for Breast Cancer Cell Co-culture Studies. Star Protocols. 1: 100197. PMID 33377091 DOI: 10.1016/j.xpro.2020.100197 |
0.306 |
|
| 2020 |
Zhang Y, Chan HL, Garcia-Martinez L, Karl DL, Weich N, Slingerland JM, Verdun RE, Morey L. Estrogen induces dynamic ERα and RING1B recruitment to control gene and enhancer activities in luminal breast cancer. Science Advances. 6: eaaz7249. PMID 32548262 DOI: 10.1126/Sciadv.Aaz7249 |
0.372 |
|
| 2020 |
Qureshi R, Picon-Ruiz M, Aurrekoetxea-Rodriguez I, Nunes de Paiva V, D'Amico M, Yoon H, Radhakrishnan R, Morata-Tarifa C, Ince T, Lippman ME, Thaller SR, Rodgers SE, Kesmodel S, Vivanco MDM, Slingerland JM. The Major Pre- and Postmenopausal Estrogens Play Opposing Roles in Obesity-Driven Mammary Inflammation and Breast Cancer Development. Cell Metabolism. 31: 1154-1172.e9. PMID 32492394 DOI: 10.1016/J.Cmet.2020.05.008 |
0.398 |
|
| 2020 |
Razavipour SF, Harikumar KB, Slingerland JM. p27 as a transcriptional regulator: New roles in development and cancer. Cancer Research. PMID 32341036 DOI: 10.1158/0008-5472.CAN-19-3663 |
0.449 |
|
| 2020 |
Razavipour S, Jang K, Yoon H, Kim M, Shin M, Zhao D, Slingerland J. Abstract 504: p27 transcriptionally coregulates STAT3 to drive cancer stem cells Cancer Research. 80: 504-504. DOI: 10.1158/1538-7445.Am2020-504 |
0.593 |
|
| 2019 |
Mustafi S, Camarena V, Qureshi R, Yoon H, Volmar CH, Huff TC, Sant DW, Zheng L, Brothers SP, Wahlestedt C, Slingerland J, Wang G. Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer. Ebiomedicine. PMID 30975544 DOI: 10.1016/J.Ebiom.2019.04.006 |
0.398 |
|
| 2019 |
Yoon H, Kim M, Jang K, Shin M, Besser A, Xiao X, Zhao D, Wander SA, Briegel K, Morey L, Minn A, Slingerland JM. p27 transcriptionally coregulates cJun to drive programs of tumor progression. Proceedings of the National Academy of Sciences of the United States of America. PMID 30877256 DOI: 10.1073/Pnas.1817415116 |
0.751 |
|
| 2019 |
Sharma U, Miller P, Saenz KM, Picon-Ruiz M, Morata-Tarifa C, Spartz A, Troness B, Park D, Seagroves T, Slingerland J, Lippman M, El-Ashry D. Abstract PD9-10: Circulating CAF/cancer stem cell co-clusters bolster breast cancer metastasis Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Pd9-10 |
0.399 |
|
| 2019 |
Slingerland J, Mark P, Hurley J, Net J, Collado-Mesa F, Lippman M, Avisar E, Yepes M, Jorda M, Gomez C. Abstract P4-15-06: Results of a randomized double blind trial of neoadjuvant anastrozole plus placebo vs anastrozole plus saracatinib for ER+ postmenopausal breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-15-06 |
0.453 |
|
| 2019 |
Leon AS, Saenz KM, Miller P, Benson A, Calfa C, Mahtani R, Slingerland J, Perez A, Vogel C, Valdes-Albini F, El-Ashry D, Lippman M. Abstract P4-01-07: A comprehensive liquid biopsy in patients undergoing neoadjuvant therapy Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-01-07 |
0.372 |
|
| 2019 |
Sexton A, Samuels S, Dooley S, Zhao W, Reis I, Hurley J, Slingerland J, Isrow D, Freedman L, Ahamad A, Kesmodel S, Takita C. Neoadjuvant Hormonal Therapy Outcomes in a Multi-Racial/Ethnic Breast Cancer Population International Journal of Radiation Oncology*Biology*Physics. 105: E6-E7. DOI: 10.1016/J.Ijrobp.2019.06.630 |
0.353 |
|
| 2018 |
Simpkins F, Jang K, Yoon H, Hew K, Kim M, Azzam DJ, Sun J, Zhao D, Ince TA, Liu W, Guo W, Wei Z, Zhang G, Mills GB, Slingerland JM. Dual Src and MEK inhibition decreases ovarian cancer growth and targets tumor initiating stem-like cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29959144 DOI: 10.1158/1078-0432.Ccr-17-3697 |
0.775 |
|
| 2018 |
Sant DW, Mustafi S, Gustafson CB, Chen J, Slingerland JM, Wang G. Vitamin C promotes apoptosis in breast cancer cells by increasing TRAIL expression. Scientific Reports. 8: 5306. PMID 29593282 DOI: 10.1038/S41598-018-23714-7 |
0.394 |
|
| 2018 |
Picon-Ruiz M, Pan C, Drewes-Elger K, Jang K, Besser A, Zaho D, Morata-Tarifa C, Kim M, Ince T, Azzam D, Wander S, Cote R, Guy H, El-Ashry D, Torne-Poyatos P, ... ... Slingerland J, et al. Abstract P6-05-01: Interactions between adipocytes and breast cancer cells stimulate cytokine production and drive Src/SOX2/miR-302b mediated malignant progression Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P6-05-01 |
0.804 |
|
| 2018 |
Miller P, Sharma U, Medina-Saenz K, Yeasky T, Picon-Ruiz M, Morata-Tarifa C, Seagroves T, Slingerland J, Lippman M, El-Ashry D. Abstract P2-01-10: Circulating CAF/CTC complexes and breast cancer metastasis Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P2-01-10 |
0.448 |
|
| 2018 |
Ruiz MP, Tarifa CM, Qureshi R, Yoon H, Shin M, Kurani H, Slingerland JM. Abstract 4501: Mammary adipocytes mediate cytokine production and malignant progression of ER-positive breast cancer through NF-kB activation Cancer Research. 78: 4501-4501. DOI: 10.1158/1538-7445.Am2018-4501 |
0.493 |
|
| 2017 |
Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. Ca: a Cancer Journal For Clinicians. PMID 28763097 DOI: 10.3322/Caac.21405 |
0.376 |
|
| 2017 |
Kim M, Jang K, Miller P, Picon-Ruiz M, Yeasky TM, El-Ashry D, Slingerland JM. VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug. Oncogene. PMID 28504716 DOI: 10.1038/Onc.2017.4 |
0.38 |
|
| 2017 |
Scott A, Bai F, Chan HL, Liu S, Slingerland JM, Robbins DJ, Capobianco AJ, Pei XH. p16 loss rescues functional decline of Brca1-deficient mammary stem cells. Cell Cycle (Georgetown, Tex.). 0. PMID 28278054 DOI: 10.1080/15384101.2017.1295185 |
0.386 |
|
| 2017 |
Jang K, Kim M, Gilbert CA, Simpkins F, Ince TA, Slingerland JM. VEGFA activates an epigenetic pathway upregulating ovarian cancer-initiating cells. Embo Molecular Medicine. PMID 28179359 DOI: 10.15252/Emmm.201606840 |
0.408 |
|
| 2017 |
Pei X, Chan H, Liu S, Scott A, Pimentel E, Slingerland J, Robbins D, Capobianco A, Bai F. Abstract P6-08-08: GATA3 inhibits breast basal-like tumorigenesis Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-08-08 |
0.447 |
|
| 2017 |
Kwak T, Drews-Elger K, Ergonul A, Braley A, Hwang G, El-Ashry D, Slingerland J, Lippman M, Hudson B. Abstract P3-06-01: Therapeutic targeting of RAGE in the tumor and tumor microenvironment inhibits breast progression and metastasis Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P3-06-01 |
0.428 |
|
| 2017 |
Inagaki A, Richardson AM, Collins SA, Hiraoka K, Kamijima S, Shorr J, Gruber H, Jolly D, Merchan J, Slingerland JM, Kasahara N. TMOD-15. TOCA 511 & TOCA FC: PRE-CLINICAL PROOF OF CONCEPT IN CNS METASTATIC BREAST CANCER Neuro-Oncology. 19: vi257-vi257. DOI: 10.1093/Neuonc/Nox168.1053 |
0.394 |
|
| 2016 |
Scott A, Bai F, Chan HL, Liu S, Ma J, Slingerland JM, Robbins DJ, Capobianco AJ, Pei XH. p16INK4a suppresses BRCA1-deficient mammary tumorigenesis. Oncotarget. PMID 27811360 DOI: 10.18632/Oncotarget.13015 |
0.506 |
|
| 2016 |
Kwak T, Drews-Elger K, Ergonul A, Miller PC, Braley A, Hwang GH, Zhao D, Besser A, Yamamoto Y, Yamamoto H, El-Ashry D, Slingerland JM, Lippman ME, Hudson BI. Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis. Oncogene. PMID 27669433 DOI: 10.1038/Onc.2016.324 |
0.48 |
|
| 2016 |
Obeid JP, Stoyanova R, Kwon D, Patel M, Padgett K, Slingerland J, Takita C, Alperin N, Yepes M, Zeidan YH. Multiparametric evaluation of preoperative MRI in early stage breast cancer: prognostic impact of peri-tumoral fat. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. PMID 27364695 DOI: 10.1016/J.Ijrobp.2015.07.611 |
0.398 |
|
| 2016 |
Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM. Erratum to: PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Research and Treatment. PMID 26993130 DOI: 10.1007/s10549-016-3752-9 |
0.625 |
|
| 2016 |
Picon-Ruiz M, Pan C, Drews-Elger K, Jang K, Besser AH, Zhao D, Morata-Tarifa C, Kim M, Ince TA, Azzam DJ, Wander SA, Wang B, Ergonul B, Datar RH, Cote RJ, ... ... Slingerland JM, et al. Interactions between Adipocytes and Breast Cancer Cells Stimulate Cytokine Production and Drive Src/Sox2/miR-302b-Mediated Malignant Progression. Cancer Research. PMID 26744520 DOI: 10.1158/0008-5472.Can-15-0927 |
0.821 |
|
| 2016 |
Kwak T, Drews-Elger K, Ergonul A, Zhao D, Besser A, Slingerland J, Lippman M, Hudson B. Abstract P2-05-07: RAGE-ligand signaling drives breast cancer metastasis through affecting cells of the tumor and microenvironment Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-05-07 |
0.512 |
|
| 2016 |
Slingerland J, Picon-Ruiz M, Jang K, Morata-Tarifa C, Pan C, Besser A, Kim M, Ince T, Howard G, El-Ashry D. Abstract P1-03-02: Estrogens contribute to cytokine upregulation and cancer stem cell recruitment upon breast cancer contact with mature human mammary adipocytes: Effects of estrogen type and adipocyte donor weight Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P1-03-02 |
0.507 |
|
| 2015 |
Hew K, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, Gu M, Wei Z, Zhang G, Brafford PA, Guo W, Lu Y, Mills GB, Slingerland JM, Simpkins F. MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26482043 DOI: 10.1158/1078-0432.Ccr-15-0534 |
0.442 |
|
| 2015 |
Zhao D, Besser AH, Wander SA, Sun J, Zhou W, Wang B, Ince T, Durante MA, Guo W, Mills G, Theodorescu D, Slingerland J. Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation. Oncogene. PMID 25684140 DOI: 10.1038/Onc.2014.473 |
0.753 |
|
| 2015 |
Zhao D, Pan C, Sun J, Gilbert C, Drews-Elger K, Azzam DJ, Picon-Ruiz M, Kim M, Ullmer W, El-Ashry D, Creighton CJ, Slingerland JM. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2. Oncogene. 34: 3107-19. PMID 25151964 DOI: 10.1038/Onc.2014.257 |
0.747 |
|
| 2015 |
Khushman MM, Gomez Arteaga A, Diaz L, Tinoco G, Dawar R, Bustinza E, Garcia MT, Fan Y, Restrepo M, Merchan JR, Sussman DA, Slingerland J, Rocha Lima CMS, Hosein PJ. Exploring phosphatase and tensin homolog (PTEN) loss via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) as a potential predictive marker for response to everolimus in patients (pts) with neuroendocrine tumors (NET). Journal of Clinical Oncology. 33: 333-333. DOI: 10.1200/Jco.2015.33.3_Suppl.333 |
0.318 |
|
| 2015 |
Simpkins F, Hew K, Azzam D, Wei Z, Zhang G, Sun J, Zhang D, Jang K, Liu W, Lu Y, Mills G, Tan I, Slingerland J. Abstract POSTER-THER-1431: Combined Src and MEK inhibition decreases ovarian cancer (OVCA) cell growth, tumorigenicity and aldehyde dehydrogenase positive tumor-initiating-cells Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Ther-1431 |
0.792 |
|
| 2015 |
Hew K, Miller P, Sun J, Wei Z, Zhang G, Lu Y, Mills G, Slingerland J, El-Ashry D, Simpkins F. Abstract AS31: MEK inhibition reverses antiestrogen resistance in ovarian cancer (OVCA) via alteration of cell cycle pathways and MAPK/estrogen regulated gene expression Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-As31 |
0.535 |
|
| 2015 |
Khushman M, Slingerland J, Fan Y, Garcia-Buitrago M, Bustinza E, Restrepo M, Sussman D, Rocha-Lima C, Hosein P. Abstract A01: Exploring phosphatase and tensin homolog (PTEN) loss as a potential predictive marker for response to everolimus in patients with pancreatic neuroendocrine tumors (PNETs) Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Pi3K14-A01 |
0.329 |
|
| 2015 |
Kwak T, Drews-Elger K, Zhao D, Besser A, Ergonul A, Slingerland JM, Lippman ME, Hudson BI. Abstract 2270: RAGE-ligand signaling drives breast cancer invasion and metastasis Cancer Research. 75: 2270-2270. DOI: 10.1158/1538-7445.Am2015-2270 |
0.528 |
|
| 2015 |
Hew K, Miller P, El-Ashry D, Wei Z, Sun J, Zhang G, Guo W, Brafford P, Mills G, Slingerland J, Simpkins F. The effects of combined MEK inhibition and antiestrogen therapy in the treatment of ovarian cancer Gynecologic Oncology. 137: 182. DOI: 10.1016/J.Ygyno.2015.01.457 |
0.376 |
|
| 2014 |
Boelens MC, Wu TJ, Nabet BY, Xu B, Qiu Y, Yoon T, Azzam DJ, Twyman-Saint Victor C, Wiemann BZ, Ishwaran H, Ter Brugge PJ, Jonkers J, Slingerland J, Minn AJ. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell. 159: 499-513. PMID 25417103 DOI: 10.1016/J.Cell.2014.09.051 |
0.767 |
|
| 2014 |
Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ME, El-Ashry D. Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures. Breast Cancer Research and Treatment. 144: 503-17. PMID 24567196 DOI: 10.1007/S10549-014-2887-9 |
0.747 |
|
| 2014 |
Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nature Reviews. Cancer. 14: 26-38. PMID 24505618 DOI: 10.1038/Nrc3622 |
0.45 |
|
| 2014 |
Zhou W, Srinivasan S, Nawaz Z, Slingerland JM. ERα, SKP2 and E2F-1 form a feed forward loop driving late ERα targets and G1 cell cycle progression. Oncogene. 33: 2341-53. PMID 23770852 DOI: 10.1038/Onc.2013.197 |
0.346 |
|
| 2014 |
Azzam D, Wahlestedt C, Slingerland J. Abstract 3042: Therapeutic targeting of distinct subsets of cancer stem cells within triple negative breast cancers Cancer Research. 74: 3042-3042. DOI: 10.1158/1538-7445.Am2014-3042 |
0.75 |
|
| 2014 |
Zhao D, Besser AH, Zhou W, Wander SA, Sun J, Durante M, Hong F, Wang B, Ince T, Briegel K, Slingerland JM. Abstract 1145: Cytoplasmic p27 promotes epithelial-mesenchymal transition and tumor progression via Twist1 upregulation Cancer Research. 74: 1145-1145. DOI: 10.1158/1538-7445.Am2014-1145 |
0.775 |
|
| 2014 |
Zhou W, Slingerland JM. Erratum: Links between oestrogen receptor activation and proteolysis: Relevance to hormone-regulated cancer therapy (Nature Reviews Cancer (2014) 14 (26-38)) Nature Reviews Cancer. 14. DOI: 10.1038/Nrc3671 |
0.39 |
|
| 2013 |
Azzam DJ, Zhao D, Sun J, Minn AJ, Ranganathan P, Drews-Elger K, Han X, Picon-Ruiz M, Gilbert CA, Wander SA, Capobianco AJ, El-Ashry D, Slingerland JM. Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses. Embo Molecular Medicine. 5: 1502-22. PMID 23982961 DOI: 10.1002/Emmm.201302558 |
0.788 |
|
| 2013 |
Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM. PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy. Breast Cancer Research and Treatment. 138: 369-81. PMID 23430223 DOI: 10.1007/S10549-012-2389-6 |
0.761 |
|
| 2013 |
Simpkins F, Garcia-Soto A, Slingerland J. New insights on the role of hormonal therapy in ovarian cancer. Steroids. 78: 530-7. PMID 23402742 DOI: 10.1016/J.Steroids.2013.01.008 |
0.421 |
|
| 2013 |
Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annual Review of Medicine. 64: 45-57. PMID 23121183 DOI: 10.1146/Annurev-Med-121211-091527 |
0.351 |
|
| 2013 |
Simpkins F, Azzam D, Slingerland JM. Abstract B50: Preclinical efficacy of combined MEK and Src inhibition: MEK inhibitor reverses resistance to Src inhibitor therapy in ovarian cancer cells Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B50 |
0.79 |
|
| 2012 |
Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, ... ... Slingerland JM, et al. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5911-23. PMID 22896656 DOI: 10.1158/1078-0432.Ccr-12-1257 |
0.805 |
|
| 2012 |
Sun J, Zhou W, Kaliappan K, Nawaz Z, Slingerland JM. ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression. Molecular Endocrinology (Baltimore, Md.). 26: 1567-77. PMID 22865929 DOI: 10.1210/Me.2012-1140 |
0.319 |
|
| 2012 |
Montero AJ, Diaz-Montero CM, Deutsch YE, Hurley J, Koniaris LG, Rumboldt T, Yasir S, Jorda M, Garret-Mayer E, Avisar E, Slingerland J, Silva O, Welsh C, Schuhwerk K, Seo P, et al. Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II-IIIc breast cancer. Breast Cancer Research and Treatment. 132: 215-23. PMID 22138748 DOI: 10.1007/S10549-011-1889-0 |
0.413 |
|
| 2012 |
Wen S, So Y, Singh K, Slingerland JM, Resnick MB, Zhang S, Ruiz V, Moss SF. Promotion of cytoplasmic mislocalization of p27 by Helicobacter pylori in gastric cancer Oncogene. 31: 1771-1780. PMID 21841827 DOI: 10.1038/Onc.2011.362 |
0.447 |
|
| 2012 |
Zhou W, Sun J, Slingerland JM. Abstract 952: The SCF F box protein, Skp2, is a key component of an E3 ubiqutin ligase that governs estrogen receptor ≤ stability Cancer Research. 72: 952-952. DOI: 10.1158/1538-7445.Am2012-952 |
0.479 |
|
| 2012 |
Azzam DJ, Elger KD, Zhao D, Ranganathan P, Capobianco T, Minn AJ, Creighton C, Picon M, Sun J, Pan C, Wander SA, Ashry DE, Slingerland JM. Abstract 3478: CD44+CD24low+progenitors in ER negative breast cancer have higher Notch1 activation, self-renewal, and chemo resistance and generate CD44+CD24negcells and tumors that metastasize Cancer Research. 72: 3478-3478. DOI: 10.1158/1538-7445.Am2012-3478 |
0.794 |
|
| 2012 |
Perez A, Neskey DM, Wen J, Goodwin JW, Slingerland J, Pereira L, Weigand S, Franzmann EJ. Abstract 2521: Targeting CD44 in head and neck squamous cell carcinoma (HNSCC) with a new humanized antibody RO5429083 Cancer Research. 72: 2521-2521. DOI: 10.1158/1538-7445.Am2012-2521 |
0.455 |
|
| 2012 |
Besser AH, Wander SA, Zhao D, Hong F, Wei JQ, Wang B, Ince T, Milikowski C, Nadji M, Briegel K, Bishopric N, Slingerland JM. Abstract 2224: Targeted PI3K/mTOR inhibition impairs tumor cell motility and bone metastatic outgrowth via modulation of p27 Cancer Research. 72: 2224-2224. DOI: 10.1158/1538-7445.Am2012-2224 |
0.752 |
|
| 2012 |
Boelens MC, Wu TJ, Yoon T, Azzam D, Slingerland JM, Minn AJ. Abstract 1505: Stroma-mediated DNA damage resistance of human breast cancer Cancer Research. 72: 1505-1505. DOI: 10.1158/1538-7445.Am2012-1505 |
0.771 |
|
| 2011 |
Wander SA, Hennessy BT, Slingerland JM. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. The Journal of Clinical Investigation. 121: 1231-41. PMID 21490404 DOI: 10.1172/Jci44145 |
0.682 |
|
| 2011 |
Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Désiré L, Slingerland J, Burnstein KL. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocrine-Related Cancer. 18: 207-19. PMID 21118977 DOI: 10.1677/Erc-10-0049 |
0.534 |
|
| 2011 |
Wander SA, Zhao D, Slingerland JM. p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 12-8. PMID 20966355 DOI: 10.1158/1078-0432.Ccr-10-0752 |
0.753 |
|
| 2011 |
Chen Y, Alvarez EA, Azzam D, Wander SA, Guggisberg N, Jordà M, Ju Z, Hennessy BT, Slingerland JM. Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo. Breast Cancer Research and Treatment. 128: 69-78. PMID 20669046 DOI: 10.1007/S10549-010-1024-7 |
0.829 |
|
| 2011 |
Azzam DJ, Drews-Elger K, Zhao D, Chendong P, Wander SA, El-Ashry D, Slingerland JM. Abstract 3335: Self-renewal, tumorigenicity and metastatic potential of CD44+ cells in ER-negative lines and dissociated primary human breast cancers is increased in CD24+ subsets Cancer Research. 71: 3335-3335. DOI: 10.1158/1538-7445.Am2011-3335 |
0.792 |
|
| 2011 |
Wander SA, Zhao D, Hong F, Pan C, Chen Y, Jorda M, Slingerland JM. Abstract 2333: The atypical tumor suppressor p27 regulates cellular proliferation, invasion, and metastasis via subcellular localization in distinct microenvironments Cancer Research. 71: 2333-2333. DOI: 10.1158/1538-7445.Am2011-2333 |
0.749 |
|
| 2010 |
Liao J, Gallas M, Pegram M, Slingerland J. Lapatinib: new opportunities for management of breast cancer. Breast Cancer (Dove Medical Press). 2: 79-91. PMID 24367169 DOI: 10.2147/BCTT.S5929 |
0.334 |
|
| 2010 |
Lobo C, Lopes G, Baez O, Castrellon A, Ferrell A, Higgins C, Hurley E, Hurley J, Reis I, Richman S, Seo P, Silva O, Slingerland J, Tukia K, Welsh C, et al. Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Research and Treatment. 123: 427-35. PMID 20585851 DOI: 10.1007/S10549-010-1002-0 |
0.327 |
|
| 2010 |
Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 723-30. PMID 20026801 DOI: 10.1200/Jco.2009.24.0143 |
0.304 |
|
| 2010 |
Pegram MD, Silva OE, Higgins C, Tukia K, Stuart M, Slingerland J. Phase IB pharmacokinetic (PK) study of Src kinase inhibitor AZD0530 plus anastrozole in postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 28: e13074-e13074. DOI: 10.1200/Jco.2010.28.15_Suppl.E13074 |
0.49 |
|
| 2010 |
Penney RB, Felty Q, Slingerland J, Roy D. Abstract 604: Erucin treatment through induction of thioredoxin reductase may alter tamoxifen resistance in LCC2 cells Cancer Research. 70: 604-604. DOI: 10.1158/1538-7445.Am10-604 |
0.458 |
|
| 2010 |
Wander SA, Hong F, Zhao D, Pan C, Larrea MD, Jorda M, Slingerland JM. Abstract 5137: The PI3K pathway regulates the actin cytoskeleton, tumor cell migration and metastasis via the atypical tumor suppressor p27 Cancer Research. 70: 5137-5137. DOI: 10.1158/1538-7445.Am10-5137 |
0.824 |
|
| 2010 |
Sudhindra A, Dammarich D, Ochoa R, Takita C, Mendiola M, Hurley J, Gluck S, Welsh C, Slingerland J, Richman S, Gomez-Fernandez C, Timothee P, Diaz A, Silva O. Abstract P3-11-09: Body Mass Index (BMI) and Survival: A Retrospective Review of Women with Triple Negative Breast Cancer (An Update) Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-11-09 |
0.305 |
|
| 2010 |
Pegram M, Silva O, Higgins C, Tukia K, Avisar E, Stuart M, Slingerland J. Abstract P2-19-03: Src Kinase Inhibition with AZD0530 Plus Anastrozole in Postmenopausal Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC) Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-19-03 |
0.47 |
|
| 2010 |
Montero A, Diaz C, Slingerland J, Pegram M, Hurley J, Welsh C, Avisar E, Seo P, Vogel C, Garrett-Mayer E, Hermann V, Baker M, Silva O, Koniaris L, Rodgers S, et al. Abstract P1-11-05: Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with Stage II-III HER-2 (-) Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P1-11-05 |
0.441 |
|
| 2010 |
Glück S, Lobo C, Lopes G, Castrellon A, Hurley J, Reis I, Richman S, Silva O, Slingerland J, Welsh C. 470 Final results of a phase II study of combination with nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy in patients with HER2-negative metastatic breast cancer European Journal of Cancer Supplements. 8: 196. DOI: 10.1016/S1359-6349(10)70491-2 |
0.375 |
|
| 2009 |
Larrea MD, Wander SA, Slingerland JM. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility. Cell Cycle (Georgetown, Tex.). 8: 3455-61. PMID 19829074 DOI: 10.4161/Cc.8.21.9789 |
0.822 |
|
| 2009 |
Larrea MD, Hong F, Wander SA, da Silva TG, Helfman D, Lannigan D, Smith JA, Slingerland JM. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proceedings of the National Academy of Sciences of the United States of America. 106: 9268-73. PMID 19470470 DOI: 10.1073/Pnas.0805057106 |
0.813 |
|
| 2009 |
Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3396-405. PMID 19451593 DOI: 10.1158/1078-0432.Ccr-08-3127 |
0.516 |
|
| 2009 |
Penney R, Slingerland J, Roy D. Redox Status Contributes to Tamoxifen-Resistant Growth of Breast Cancer. Cancer Research. 69: 5134-5134. DOI: 10.1158/0008-5472.Sabcs-09-5134 |
0.517 |
|
| 2008 |
Gluck S, Lobo C, Reis I, Lopes G, Carmody C, Tukia K, Hurley J, Seo P, Silva O, Slingerland J, Welsh C. Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1089. PMID 27951041 DOI: 10.1200/Jco.2008.26.15_Suppl.1089 |
0.343 |
|
| 2008 |
Larrea MD, Liang J, Da Silva T, Hong F, Shao SH, Han K, Dumont D, Slingerland JM. Phosphorylation of p27Kip1 regulates assembly and activation of cyclin D1-Cdk4. Molecular and Cellular Biology. 28: 6462-72. PMID 18710949 DOI: 10.1128/Mcb.02300-07 |
0.785 |
|
| 2008 |
Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, Slingerland JM. mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Molecular Cell. 30: 701-11. PMID 18570873 DOI: 10.1016/J.Molcel.2008.04.027 |
0.828 |
|
| 2008 |
Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nature Reviews. Cancer. 8: 253-67. PMID 18354415 DOI: 10.1038/Nrc2347 |
0.55 |
|
| 2007 |
Sun J, Nawaz Z, Slingerland JM. Long-range activation of GREB1 by estrogen receptor via three distal consensus estrogen-responsive elements in breast cancer cells. Molecular Endocrinology (Baltimore, Md.). 21: 2651-62. PMID 17666587 DOI: 10.1210/Me.2007-0082 |
0.342 |
|
| 2007 |
Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, Chun K, Hennessy B, Mills GB, Nawaz Z, Slingerland JM. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. The Journal of Clinical Investigation. 117: 2205-15. PMID 17627304 DOI: 10.1172/Jci21739 |
0.31 |
|
| 2007 |
Govindarajan B, Sligh JE, Vincent BJ, Li M, Canter JA, Nickoloff BJ, Rodenburg RJ, Smeitink JA, Oberley L, Zhang Y, Slingerland J, Arnold RS, Lambeth JD, Cohen C, Hilenski L, et al. Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. The Journal of Clinical Investigation. 117: 719-29. PMID 17318262 DOI: 10.1172/Jci30102 |
0.411 |
|
| 2007 |
Chu I, Sun J, Arnaout A, Kahn H, Hanna W, Narod S, Sun P, Tan CK, Hengst L, Slingerland J. p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell. 128: 281-94. PMID 17254967 DOI: 10.1016/J.Cell.2006.11.049 |
0.566 |
|
| 2007 |
Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM, Mills GB. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nature Cell Biology. 9: 218-24. PMID 17237771 DOI: 10.1038/Ncb1537 |
0.805 |
|
| 2007 |
Han HS, Doliny P, Blaya M, Gluck S, Slingerland J, Silva O, Welsh C, Hurley J. Dose-dense docetaxel, carboplatinum and trastuzumab (ddTCH) as neoadjuvant therapy for human epidermal receptor 2 (HER2) positive breast cancer Journal of Clinical Oncology. 25: 11003-11003. DOI: 10.1200/Jco.2007.25.18_Suppl.11003 |
0.399 |
|
| 2006 |
Dhananjayan SC, Ramamoorthy S, Khan OY, Ismail A, Sun J, Slingerland J, O'Malley BW, Nawaz Z. WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Molecular Endocrinology (Baltimore, Md.). 20: 2343-54. PMID 16772533 DOI: 10.1210/Me.2005-0533 |
0.309 |
|
| 2006 |
Silva OE, Lopes G, Morgensztern D, Lobo C, Abdullah S, Doliny P, Slingerland J, Gluck S, Santos E, Welsh C, Hurley J. Split, low-dose docetaxel (D) and low-dose capecitabine (C) is an active regimen in metastatic breast cancer with minimal toxicity Journal of Clinical Oncology. 24: 10618-10618. DOI: 10.1200/Jco.2006.24.18_Suppl.10618 |
0.342 |
|
| 2005 |
Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM. Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis. Breast Cancer Research : Bcr. 7: R1153-8. PMID 16457695 DOI: 10.1186/Bcr1342 |
0.374 |
|
| 2005 |
Sandhu C, Connor M, Kislinger T, Slingerland J, Emili A. Global protein shotgun expression profiling of proliferating mcf-7 breast cancer cells. Journal of Proteome Research. 4: 674-89. PMID 15952714 DOI: 10.1021/Pr0498842 |
0.464 |
|
| 2005 |
Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Research. 65: 18-25. PMID 15665275 |
0.458 |
|
| 2005 |
Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, Wu Y, Lee V, Slingerland J, Dumont D, Yang BB. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Molecular Biology of the Cell. 16: 1330-40. PMID 15635104 DOI: 10.1091/Mbc.E04-04-0295 |
0.362 |
|
| 2004 |
Alkarain A, Jordan R, Slingerland JM. p27 Deregulation in Breast Cancer: Prognostic Significance and Implications for Therapy Journal of Mammary Gland Biology and Neoplasia. 9: 67-80. PMID 15082919 DOI: 10.1023/B:Jomg.0000023589.00994.5E |
0.564 |
|
| 2003 |
Alkarain A, Slingerland J. Deregulation of p27 by oncogenic signaling and its prognostic significance in breast cancer. Breast Cancer Research : Bcr. 6: 13-21. PMID 14680481 DOI: 10.1186/Bcr722 |
0.561 |
|
| 2003 |
Liang J, Slingerland JM. Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle (Georgetown, Tex.). 2: 339-45. PMID 12851486 DOI: 10.4161/Cc.2.4.433 |
0.459 |
|
| 2003 |
Connor MK, Kotchetkov R, Cariou S, Resch A, Lupetti R, Beniston RG, Melchior F, Hengst L, Slingerland JM. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis. Molecular Biology of the Cell. 14: 201-13. PMID 12529437 DOI: 10.1091/Mbc.E02-06-0319 |
0.437 |
|
| 2002 |
Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nature Medicine. 8: 1153-60. PMID 12244302 DOI: 10.1038/Nm761 |
0.588 |
|
| 2002 |
Donovan JC, Rothenstein JM, Slingerland JM. Non-malignant and tumor-derived cells differ in their requirement for p27Kip1 in transforming growth factor-beta-mediated G1 arrest. The Journal of Biological Chemistry. 277: 41686-92. PMID 12202478 DOI: 10.1074/Jbc.M204307200 |
0.414 |
|
| 2002 |
Ciarallo S, Subramaniam V, Hung W, Lee JH, Kotchetkov R, Sandhu C, Milic A, Slingerland JM. Altered p27(Kip1) phosphorylation, localization, and function in human epithelial cells resistant to transforming growth factor beta-mediated G(1) arrest. Molecular and Cellular Biology. 22: 2993-3002. PMID 11940657 DOI: 10.1128/Mcb.22.9.2993-3002.2002 |
0.454 |
|
| 2001 |
Petrocelli T, Slingerland JM. PTEN deficiency: A role in mammary carcinogenesis Breast Cancer Research. 3: 356-360. PMID 11737885 DOI: 10.1186/Bcr322 |
0.409 |
|
| 2001 |
Donovan JCH, Milic A, Slingerland JM. Constitutive MEK/MAPK Activation Leads to p27Kip1 Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells Journal of Biological Chemistry. 276: 40888-40895. PMID 11527971 DOI: 10.1074/Jbc.M106448200 |
0.6 |
|
| 2001 |
Gstaiger M, Jordan R, Lim M, Catzavelos C, Mestan J, Slingerland J, Krek W. Skp2 is oncogenic and overexpressed in human cancers Proceedings of the National Academy of Sciences of the United States of America. 98: 5043-5048. PMID 11309491 DOI: 10.1073/Pnas.081474898 |
0.483 |
|
| 2000 |
Donovan J, Slingerland J. Transforming growth factor-beta and breast cancer: Cell cycle arrest by transforming growth factor-beta and its disruption in cancer. Breast Cancer Research : Bcr. 2: 116-24. PMID 11250701 DOI: 10.1186/Bcr43 |
0.428 |
|
| 2000 |
Slingerland J. Transforming growth factor-beta and breast cancer: Introduction. Breast Cancer Research : Bcr. 2: 91. PMID 11250697 DOI: 10.1186/Bcr39 |
0.318 |
|
| 2000 |
Chappuis PO, Kapusta L, Bégin LR, Wong N, Brunet JS, Narod SA, Slingerland J, Foulkes WD. Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 4045-52. PMID 11118465 DOI: 10.1200/Jco.2000.18.24.4045 |
0.426 |
|
| 2000 |
Sandhu C, Donovan J, Bhattacharya N, Stampfer M, Worland P, Slingerland J. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells. Oncogene. 19: 5314-5323. PMID 11103932 DOI: 10.1038/Sj.Onc.1203908 |
0.372 |
|
| 2000 |
Petrocelli T, Slingerland J. UVB induced cell cycle checkpoints in an early stage human melanoma line, WM35. Oncogene. 19: 4480-4490. PMID 11002421 DOI: 10.1038/Sj.Onc.1203808 |
0.461 |
|
| 2000 |
Cariou S, Donovan JCH, Flanagan WM, Milic A, Bhattacharya N, Slingerland JM. Down-regulation of p21WAF1/CIP1 or p27KiP1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells Proceedings of the National Academy of Sciences of the United States of America. 97: 9042-9046. PMID 10908655 DOI: 10.1073/Pnas.160016897 |
0.577 |
|
| 2000 |
Slingerland J, Pagano M. Regulation of the Cdk inhibitor p27 and its deregulation in cancer Journal of Cellular Physiology. 183: 10-17. PMID 10699961 DOI: 10.1002/(Sici)1097-4652(200004)183:1<10::Aid-Jcp2>3.0.Co;2-I |
0.521 |
|
| 2000 |
Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J. Involvement of p27(Kip1) in G1 arrest by high dose 5α-dihydrotestosterone in LNCaP human prostate cancer cells Oncogene. 19: 670-679. PMID 10698512 DOI: 10.1038/Sj.Onc.1203369 |
0.376 |
|
| 1999 |
Tsihlias J, Kapusta L, Slingerland JM. The Prognostic Significance of Altered Cyclin-Dependent Kinase Inhibitors in Human Cancer Annual Review of Medicine. 50: 401-423. PMID 10073286 DOI: 10.1146/Annurev.Med.50.1.401 |
0.557 |
|
| 1999 |
Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21(WAF1/CIP1) is lost during progression of human malignant melanoma Oncogene. 18: 1023-1032. PMID 10023678 DOI: 10.1038/Sj.Onc.1202382 |
0.405 |
|
| 1999 |
Catzavelos C, Tsao MS, DeBoer G, Bhattacharya N, Shepherd FA, Slingerland JM. Reduced expression of the cell cycle inhibitor p27(Kip1) in non-small cell lung carcinoma: A prognostic factor independent of ras Cancer Research. 59: 684-688. PMID 9973218 |
0.33 |
|
| 1998 |
Cariou S, Catzavelos C, Slingerland JM. Prognostic implications of expression of the cell cycle inhibitor protein p27(Kip1) Breast Cancer Research and Treatment. 52: 29-41. PMID 10066070 DOI: 10.1023/A:1006154900130 |
0.56 |
|
| 1998 |
Lauper N, Beck AR, Cariou S, Richman L, Hofmann K, Reith W, Slingerland JM, Amati B. Cyclin E2: a novel CDK2 partner in the late G1 and S phases of the mammalian cell cycle. Oncogene. 17: 2637-43. PMID 9840927 DOI: 10.1038/Sj.Onc.1202477 |
0.349 |
|
| 1998 |
St. Croix B, Sheehan C, Rak JW, Fłorenes VA, Slingerland JM, Kerbel RS. E-cadherin-dependent growth suppression is mediated by the cyclin- dependent kinase inhibitor p27(KIP1) Journal of Cell Biology. 142: 557-571. PMID 9679152 DOI: 10.1083/Jcb.142.2.557 |
0.434 |
|
| 1998 |
Slingerland J, Pagano M. Regulation of the cell cycle by the ubiquitin pathway Results and Problems in Cell Differentiation. 22: 133-147. PMID 9670322 DOI: 10.1007/978-3-540-69686-5_6 |
0.35 |
|
| 1998 |
Flørenes VA, Mælandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27(Kip1) in malignant melanoma: Inverse correlation with disease-free survival American Journal of Pathology. 153: 305-312. PMID 9665492 DOI: 10.1016/S0002-9440(10)65572-1 |
0.459 |
|
| 1998 |
Tsihlias J, Kapusta LR, DeBoer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N, Catzavelos GC, Klotz LH, Slingerland JM. Loss of cyclin-dependent kinase inhibitor p27(Kip1) is a novel prognostic factor in localized human prostate adenocarcinoma Cancer Research. 58: 542-548. PMID 9458103 |
0.329 |
|
| 1997 |
Radeva G, Petrocelli T, Behrend E, Leung-Hagesteijn C, Filmus J, Slingerland J, Dedhar S. Overexpression of the integrin-linked kinase promotes anchorage- independent cell cycle progression Journal of Biological Chemistry. 272: 13937-13944. PMID 9153256 DOI: 10.1074/Jbc.272.21.13937 |
0.484 |
|
| 1997 |
Sandhu C, Garbe J, Bhattacharya N, Daksis J, Pan CH, Yaswen P, Koh J, Slingerland JM, Stampfer MR. Transforming growth factor β stabilizes p15(INK4B) protein, increases p15(INK4B)-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells Molecular and Cellular Biology. 17: 2458-2467. PMID 9111314 DOI: 10.1128/Mcb.17.5.2458 |
0.422 |
|
| 1997 |
LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes & Development. 11: 847-62. PMID 9106657 DOI: 10.1101/Gad.11.7.847 |
0.459 |
|
| 1997 |
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM. Decreased levels of the cell-cycle inhibitor p27(Kip1) protein: Prognostic implications in primary breast cancer Nature Medicine. 3: 227-230. PMID 9018244 DOI: 10.1038/Nm0297-227 |
0.573 |
|
| 1997 |
Tsihlias J, Kapusta L, Slingerland JM, Charles Catzavelos G, Deboer G, Klotz LH. Prognostic role of p-27, a cyclin dependent kinase inhibitor (cdk-i) in localized prostate cancer British Journal of Urology. 80: 232. |
0.367 |
|
| 1996 |
Florenes VA, Bhattacharya N, Bani MR, Ben-David Y, Kerbel RS, Slingerland JM. TGF-β mediated G1 arrest in a human melanoma cell line lacking p15(INK4B): evidence for cooperation between p21(Cip1/WAF1) and p27(Kip1) Oncogene. 13: 2447-2457. PMID 8957087 |
0.349 |
|
| 1996 |
St. Croix B, Flørenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS. Impact of the cyclin-dependent kinase inhibitor p27(Kip1) on resistance of tumor cells to anticancer agents Nature Medicine. 2: 1204-1210. PMID 8898746 DOI: 10.1038/Nm1196-1204 |
0.49 |
|
| 1996 |
Petrocelli T, Poon R, Drucker DJ, Slingerland JM, Rosen CF. UVB radiation induces p21Cip1/WAF1 and mediates G1 and S phase checkpoints Oncogene. 12: 1387-1396. PMID 8622854 |
0.312 |
|
| 1995 |
Reed SI, Bailly E, Dulic V, Hengst L, Resnitzky D, Slingerland J. G1 control in mammalian cells. Journal of Cell Science. Supplement. 18: 69-73. PMID 7883795 DOI: 10.1242/Jcs.1994.Supplement_18.10 |
0.382 |
|
| 1994 |
Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. A cell cycle-regulated inhibitor of cyclin-dependent kinases Proceedings of the National Academy of Sciences of the United States of America. 91: 5291-5295. PMID 8202483 DOI: 10.1073/Pnas.91.12.5291 |
0.47 |
|
| 1994 |
Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells Molecular and Cellular Biology. 14: 3683-3694. PMID 8196612 DOI: 10.1128/Mcb.14.6.3683 |
0.362 |
|
| 1993 |
Slingerland JM, Jenkins JR, Benchimol S. The transforming and suppressor functions of p53 alleles: effects of mutations that disrupt phosphorylation, oligomerization and nuclear translocation. The Embo Journal. 12: 1029-37. PMID 8458321 DOI: 10.1002/J.1460-2075.1993.Tb05744.X |
0.354 |
|
| 1991 |
Slingerland JM, Minden MD, Benchimol S. Mutation of the p53 gene in human acute myelogenous leukemia Blood. 77: 1500-1507. PMID 2009369 DOI: 10.1182/Blood.V77.7.1500.Bloodjournal7771500 |
0.385 |
|
| 1991 |
Lishner M, Slingerland J, Barr J, Panzarella T, Degendorfer P, Sutcliffe S. Second malignant neoplasms in patients with non Hodgkin's lymphoma. Hematological Oncology. 9: 169-79. PMID 1937408 DOI: 10.1002/Hon.2900090308 |
0.349 |
|
| 1991 |
Slingerland JM, Benchimol S. Transforming activity of mutant human p53 alleles Journal of Cellular Physiology. 148: 391-395. PMID 1918170 DOI: 10.1002/Jcp.1041480309 |
0.337 |
|
| Show low-probability matches. |